TOP - September 2022 Vol 15, No 5
Trastuzumab Deruxtecan Represents New Standard of Care for Patients with HER2-Low Metastatic Breast Cancer
Targeting HER2 with the antibody–drug conjugate fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) provided clinically meaningful benefits for patients with HER2-low metastatic breast cancer, according to findings presented at the 2022 American Society of Clinical Oncology Annual Meeting.
The addition of the PARP inhibitor niraparib (Zejula) to abiraterone acetate (Zytiga) plus prednisone (AAP) led to a significant improvement in radiographic progression-free survival (PFS) versus AAP alone in men with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations, according to the final analysis of the primary end point of a phase 3 trial.
Immune checkpoint inhibitor therapy in advanced biliary tract cancer (BTC) is associated with limited clinical activity.
More than 50% of adults with refractory or relapsed large B-cell lymphoma (LBCL) who were not deemed candidates for high-dose chemotherapy and hematopoietic stem-cell transplantation (HSCT) had complete responses (CRs) following treatment with the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (Breyanzi).
The September issue of The Oncology Pharmacist (TOP) features news and updates relevant to today’s pharmacy professionals working in the field of oncology.
Darolutamide plus ADT and Docetaxel Improves Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer
Treatment with the androgen receptor inhibitor darolutamide (Nubeqa), in combination with androgen-deprivation therapy (ADT) and docetaxel, significantly improved overall survival (OS) compared with ADT and docetaxel alone in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to recent results from the phase 3 ARASENS clinical trial, which were simultaneously published in the New England Journal of Medicine.
>Sotorasib (Lumakras) continues to demonstrate durable efficacy in non–small-cell lung cancer (NSCLC) with KRAS p.G12C mutation at 2-year follow-up of the phase 2 CodeBreaK 100 clinical trial.
Black Patients with Cancer and COVID-19 More Likely to Have Treatment Disruptions Than White Patients
According to data from the American Society of Clinical Oncology (ASCO) Survey on COVID-19 in Oncology Registry, black or African-American patients with cancer and COVID-19 were more likely than non-Hispanic white patients to experience delays or disruptions in cancer treatment during the pandemic.
The theme for the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting selected by 2021-2022 ASCO President Everett E. Vokes, MD, John E. Ultmann Professor of Medicine, and Chair, Department of Medicine, University of Chicago Duchossois Center for Advanced Medicine, Hyde Park, was advancing equitable cancer care through innovation.
High-Risk Localized Renal-Cell Carcinoma May Benefit from Neoadjuvant Combination of Avelumab and Axitinib
The neoadjuvant combination of avelumab (Bavencio) and axitinib (Inlyta) resulted in a partial response (PR) rate of 30% in patients with localized renal-cell carcinoma (RCC) at high risk for relapse after nephrectomy, according to results from the phase 2 NeoAvAx clinical trial.
Page 1 of 2
Results 1 - 10 of 12
Results 1 - 10 of 12